Bibliography:
1. Noris M, Caprioli J, Bresin E, Mossali C, Pianetti G, Gamba S, et al. Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol. 2010 Oct;5(10):1844–59.
2. Flynn JT, Kaelber DC, Baker-Smith CM, Blowey D, Carroll AE, Daniels SR, et al. Clinical Practice Guideline for Screening and Management of High Blood Pressure in Children and Adolescents. Pediatrics. 2017 Sep 1;140(3):e20171904.
3. WHO | Haemoglobin concentrations for the diagnosis of anaemia and assessment of severity [Internet]. WHO. World Health Organization; [cited 2020 Aug 11]. Available from: http://www.who.int/vmnis/indicators/haemoglobin/en/
4. Zini G, d’Onofrio G, Briggs C, Erber W, Jou JM, Lee SH, et al. ICSH recommendations for identification, diagnostic value, and quantitation of schistocytes. Int J Lab Hematol. 2012 Apr;34(2):107–16.
5. Kellum JA, Lameire N. Diagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (Part 1). Crit Care. 2013;17(1):204.
6. Schwartz GJ, Muñoz A, Schneider MF, Mak RH, Kaskel F, Warady BA, et al. New equations to estimate GFR in children with CKD. J Am Soc Nephrol. 2009 Mar;20(3):629–37.
7. Srivastava RN, Moudgil A, Bagga A, Vasudev AS. Hemolytic uremic syndrome in children in northern India. Pediatr Nephrol. 1991 May;5(3):284–8.
8. Hughes DA, Beattie TJ, Murphy AV. Haemolytic uraemic syndrome: 17 years’ experience in a Scottish paediatric renal unit. Scott Med J. 1991 Feb;36(1):9–12.
9. Binda ki Muaka P, Proesmans W, Eeckels R. The haemolytic uraemic syndrome in childhood: a study of the long-term prognosis. Eur J Pediatr. 1981 Jul;136(3):237–43.
10. Loirat C, Sonsino E, Varga Moreno A, Pillion G, Mercier JC, Beaufils F, et al. Hemolytic-uremic syndrome: an analysis of the natural history and prognostic features. Acta Paediatr Scand. 1984 Jul;73(4):505–14.
11. Sinha A, Gulati A, Saini S, Blanc C, Gupta A, Gurjar BS, et al. Prompt plasma exchanges and immunosuppressive treatment improves the outcomes of anti-factor H autoantibody-associated hemolytic uremic syndrome in children. Kidney International. 2014 May 1;85(5):1151–60.
12. Fremeaux-Bacchi V, Fakhouri F, Garnier A, Bienaimé F, Dragon-Durey M-A, Ngo S, et al. Genetics and Outcome of Atypical Hemolytic Uremic Syndrome: A Nationwide French Series Comparing Children and Adults. CJASN. 2013 Apr 5;8(4):554–62.
13. Dragon-Durey M-A, Sethi SK, Bagga A, Blanc C, Blouin J, Ranchin B, et al. Clinical features of anti-factor H autoantibody-associated hemolytic uremic syndrome. J Am Soc Nephrol. 2010 Dec;21(12):2180–7.
14. Gianantonio CA, Vitacco M, Mendilaharzu F, Gallo GE, Sojo ET. The hemolytic-uremic syndrome. Nephron. 1973;11(2):174–92.
15. Tsai H-M. Atypical Hemolytic Uremic Syndrome: Beyond Hemolysis and Uremia. Am J Med. 2019 Feb;132(2):161–7.
16. Schapkaitz E, Mezgebe MH. The Clinical Significance of Schistocytes: A Prospective Evaluation of the International Council for Standardization in Hematology Schistocyte Guidelines. Turk J Haematol. 2017 Mar;34(1):59–63.
17. Janssen van Doorn K, Dirinck E, Verpooten GA, Couttenye MM. Complement factor H mutation associated with membranoproliferative glomerulonephritis with transformation to atypical haemolytic uraemic syndrome. Clin Kidney J. 2013 Apr;6(2):216–9.
18. Kaplan BS, Thomson PD, MacNab GM. Letter: Serum-complement levels in haemolytic-uraemic syndrome. Lancet. 1973 Dec 29;2(7844):1505–6.
19. Stühlinger W, Kourilsky O, Kanfer A, Sraer JD. Letter: Haemolytic-uraemic syndrome: evidence for intravascular C3 activation. Lancet. 1974 Sep 28;2(7883):788–9.
20. Song D, Liu X-R, Chen Z, Xiao H-J, Ding J, Sun S-Z, et al. The clinical and laboratory features of Chinese Han anti-factor H autoantibody-associated hemolytic uremic syndrome. Pediatr Nephrol. 2017;32(5):811–22.
21. Hofer J, Janecke AR, Zimmerhackl LB, Riedl M, Rosales A, Giner T, et al. Complement factor H-related protein 1 deficiency and factor H antibodies in pediatric patients with atypical hemolytic uremic syndrome. Clin J Am Soc Nephrol. 2013 Mar;8(3):407–15.
22. Khandelwal P, Birla S, Bhatia D, Puraswani M, Saini H, Sinha A, et al. Mutations in membrane cofactor protein (CD46) gene in Indian children with hemolytic uremic syndrome. Clin Kidney J. 2018 Apr 1;11(2):198–203.
23. Zäuner I, Bach D, Braun N, Krämer BK, Fünfstück R, Helmchen U, et al. Predictive value of initial histology and effect of plasmapheresis on long-term prognosis of rapidly progressive glomerulonephritis. Am J Kidney Dis. 2002 Jan;39(1):28–35.
24. Sana G, Dragon-Durey M-A, Charbit M, Bouchireb K, Rousset-Rouvière C, Bérard E, et al. Long-term remission of atypical HUS with anti-factor H antibodies after cyclophosphamide pulses. Pediatr Nephrol. 2014 Jan;29(1):75–83.
25. Lara PN, Coe TL, Zhou H, Fernando L, Holland PV, Wun T. Improved survival with plasma exchange in patients with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Am J Med. 1999 Dec;107(6):573–9.
26. Noris M, Remuzzi G. Hemolytic Uremic Syndrome. JASN. 2005 Apr 1;16(4):1035–50.
27. Loirat C, Frémeaux-Bacchi V. Atypical hemolytic uremic syndrome. Orphanet J Rare Dis. 2011 Sep 8;6:60.
Table 1 : Baseline clinical and laboratory parameters in children with aHUS.
Table 2 : Laboratory parameters at admission, at peak and at remission.
Figure 1 : Proportion of symptoms at the time of presentation.
Figure 2 : Complement abnormalities in our study population.
Figure 3: Analysis of CD46 (Membrane Cofactor Protein: MCP) expression on granulocytes of patient with HUS versus healthy control. Granulocytes were gated on FSC vs SSC dot plot. Autofluorescence is indicated by red (Control) and blue (patient) lines. Positivity for CD46 is shown by pink (patient) and green (control) lines. Median fluorescence intensity (MFI) is mentioned on the top of graph. Flowcytometry was performed within two hours of sample receiving.